{
    "nctId": "NCT03471117",
    "officialTitle": "Targeting ADMA With Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients",
    "inclusionCriteria": "* CKD patients classified as Stage 3 and 4 of National Kidney Foundation Classification with estimated glomerular filtration rate (GFR) between 15 and 59 mL/min/1.73 m2 according to the Modification of Diet in Renal Disease (MDRD) formula based on serum creatinine, age, gender, and race.\n* Men and women 35 to 70 years of age\n* Must have minimum age of 35 Years\n* Must have maximum age of 70 Years",
    "exclusionCriteria": "* Allergy to Glitazones\n* Myocardial infarction\n* Heart failure\n* Angina\n* History of kidney stones\n* Liver disease (abnormal liver enzymes)\n* Anemia (hemoglobin \\<8 g/dl)\n* Cancer with current treatment\n* Previous organ transplantation\n* Immunosuppressant therapy\n* Human immunodeficiency virus infection\n* Pregnancy or lactating\n* Current tobacco use\n* Dilantin and oral contraceptive usage due to potential drug interaction with glitazones\n* Self-identified history of hypoglycemia"
}